Integrated BioPharma subsidiary Manhattan Drug names Michael Richtmyer head of operations
Reuters2026/08/20 15:08- Manhattan Drug, a wholly owned unit of Integrated BioPharma, named Michael G. Richtmyer head of operations, effective Aug. 3, 2026.
- Richtmyer will run manufacturing performance, supply chain reliability, quality systems, productivity, scalable growth across the contract supplement manufacturer.
- He most recently led Tishcon as president, overseeing two contract manufacturing sites with responsibility for operations, quality, sales, budgets.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
SK Hynix CEO: Memory chip shortage will persist until 2030
Crypto prices
More
